NCT05559385 is a NA clinical trial of Robot-Assissted Therapy in Stroke, sponsored by Emresenocak.

Who is sponsoring NCT05559385?

NCT05559385 is sponsored by Emresenocak.

What drugs are being tested in NCT05559385?

Interventions in NCT05559385: Robot-Assissted Therapy, Conventional Rehabilitation.

Is NCT05559385 still recruiting?

NCT05559385 is currently completed. Last updated 3 October 2022.

Last reviewed 2022-10-03 · How we verify

NCT05559385

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Is Robot-Assisted Therapy Effective for the Upper Extremity Following a Stroke

Completed NA Last updated 3 October 2022

What this trial tests

NA trial testing Robot-Assissted Therapy in Stroke in 41 participants. Completed in 5 August 2022.

Timeline

2 January 2022

Primary endpoint
17 June 2022

5 August 2022

Quick facts

Lead sponsor	Emresenocak
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	2 January 2022
Primary completion	17 June 2022
Estimated completion	5 August 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Robot-Assissted Therapy
Conventional Rehabilitation

Conditions studied

Stroke — all drugs for Stroke →

Sponsor

Emresenocak

Who can join

Adults 40 to 85, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to investigate the effects on upper-limb motor function of the addition of robotic rehabilitation (RR) and conventional rehabilitation (CR) treatments to intensive trunk rehabilitation (ITR). A total of 41 subacute stroke patients were randomly allocated to two groups: RR and CR. Both groups received the same ITR procedure (6x5x60 weeks/days/minutes). Following ITR, a robot-assisted rehabilitation program of 60 minutes, five days a week, for six weeks, was applied to the RR group, and an individualized upper extremity rehabilitation program to the CR group. Evaluations were made at baseline and after six weeks using the Trunk Impairment Scale (TIS), Fugl-Meyer Upper Extremity Motor Evaluation Scale (FMA-UE), and Wolf Motor Function Test (WMFT).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Is the robotic rehabilitation that is added to intensive body rehabilitation effective for maximization of upper extremity motor recovery following a stroke? A randomized controlled study.
Şenocak E, Korkut E, Aktürk A, Ozer AY. · · 2023 · cited 4× · PMID 36897464 · DOI 10.1007/s10072-023-06739-3

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other Emresenocak trials

Trials by the same sponsor.

NCT04803669 — The Effect of Instrument-assisted Soft Tissue Mobilization Technique on Neck Pain · NA · completed
NCT04330911 — The Effects of Aerobic Exercises on Exercise Capacity in Type-2 Diabetes Mellitus · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05559385 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emresenocak
Last refreshed: 3 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05559385.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing